AWM
NKTR icon

Avior Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

Avior Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13
Closed -$186 – 3186
2024
Q1 		$186 Buy
+13
New +$136 ﹤0.01% 2904
2018
Q4 		– Sell
-101
Closed -$92K – 741
2018
Q3 		$92K Sell
101
-46
-31% -$39.3K 0.02% 444
2018
Q2 		$108K Sell
147
-48
-25% -$55.3K 0.02% 435
2018
Q1 		$311K Sell
195
-348
-64% -$448K 0.07% 227
2017
Q4 		$487K Buy
543
+510
+1,545% +$302K 0.11% 171
2017
Q3 		$12K Buy
+33
New +$10.3K ﹤0.01% 317

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avior Wealth Management's NKTR Position: Q2 2024 in Review

Avior Wealth Management sold out of Nektar Therapeutics (NKTR) in Q2 2024, closing a stake of 13 shares — an estimated $186 sold.

Avior Wealth Management first reported a position in NKTR in Q3 2017 and held it in 6 quarters. The position peaked at $487K in Q4 2017. 133 funds tracked by Wall St. Rank hold NKTR as of Q2 2024.

  • Avior Wealth Management reported no remaining Nektar Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 13 Nektar Therapeutics shares in Q2 2024, an estimated $186.
  • Avior Wealth Management first reported a position in Nektar Therapeutics in Q3 2017 and held it in 6 quarters.
  • Avior Wealth Management's Nektar Therapeutics position peaked at $487K in Q4 2017.
  • 133 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.